IPHA (Innate Pharma) Valuation Rank


IPHA Innate Pharma SA IPHA
41 GF Score
Price $1.90
GF Value $0.16
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Innate Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Innate Pharma Valuation Rank Related Terms

IPHA
41GF Score
Innate Pharma SA IPHA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Innate Pharma (IPHA) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of $1.90 is trading 1086.9% above its estimated GF Value™ of $0.16. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for IPHA:

  • Valuation Rank:
  • GF Value™: $0.16 vs. price of $1.90 (1086.9% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the IPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Address 117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
41GF Score

Get the complete analysis for IPHA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.90
Price
$0.16
GF Value